Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

Medicine & Life Sciences

• cediranib 100%
• Bevacizumab 64%
• Vascular Endothelial Growth Factor A 50%
• Neoplasms 18%
• Circulating Neoplastic Cells 13%
• Hypertension 10%
• Hemorrhage 10%
• Thrombocytopenia 3 9%
• Alveolar Soft Part Sarcoma 8%
• Pharmacokinetics 7%
• Inflammatory Breast Neoplasms 7%
• Synovial Sarcoma 7%
• Vascular Endothelial Growth Factor Receptor 6%
• Oxides 6%
• Hemoptysis 6%
• National Cancer Institute (U.S.) 6%
• Basal Cell Carcinoma 5%
• Intracranial Hemorrhages 5%
• Nitrates 5%
• Terminology 5%
• Chest Pain 5%
• Nitric Oxide Synthase 5%
• Protein-Tyrosine Kinases 4%
• Fatigue 4%
• Area Under Curve 4%
• Cell Count 3%
• Central Nervous System 3%
• Safety 3%